Zurampic license will see AstraZeneca supply Ironwood

By Gareth Macdonald

- Last updated on GMT


Related tags Food and drug administration

AstraZeneca will supply Ironwood Pharmaceuticals with the API and finished dosage form of the gout drug Zurampic under the licensing deal agreed this week.

Ironwood was granted​ US development and commercialisation rights to the drug by AstraZeneca in return for a $100m payment and sales-related milestones of up to $165m.

AstraZeneca’s decision to license Zurampic (lesinurad) – which was approved by the US Food and Drug Administration (FDA) in December​ - is part of the “externalization” strategy the Anglo-Swedish firm has used to generate money to invest in R&D.

According to AstraZeneca’s financial​ results, licensing out non-core products generated $1.06bn in revenue in 2015.

Supply deal

Under the agreement, AZ Pharmaceuticals will manufacture and supply commercial supply Zurampic for Ironwood for an interim period until the latter firm takes over production at an unspecified point in the future.

In addition, AstraZeneca’s Ardea Biosciences subsidiary will develop a drug combining lesinurad and allopurinol on Ironwood’s behalf in exchange.

Ironwood can also negotiate for US development, manufacturing and commercialize rights to gout treatments combining verinurad – another API owned by Ardea – and other ingredients. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us